Bard College

Bard Digital Commons
Senior Projects Spring 2015

Bard Undergraduate Senior Projects

Spring 2015

Investigating the binding potential and downstream effects of
ferrocene/ ruthenium (III) complexes with RNA
Mildred Apollo Kissai
Bard College, mk4425@bard.edu

Follow this and additional works at: https://digitalcommons.bard.edu/senproj_s2015
Part of the Biochemistry Commons, and the Laboratory and Basic Science Research Commons

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Recommended Citation
Kissai, Mildred Apollo, "Investigating the binding potential and downstream effects of ferrocene/
ruthenium (III) complexes with RNA" (2015). Senior Projects Spring 2015. 152.
https://digitalcommons.bard.edu/senproj_s2015/152

This Open Access work is protected by copyright and/or
related rights. It has been provided to you by Bard
College's Stevenson Library with permission from the
rights-holder(s). You are free to use this work in any way
that is permitted by the copyright and related rights. For
other uses you need to obtain permission from the rightsholder(s) directly, unless additional rights are indicated by
a Creative Commons license in the record and/or on the
work itself. For more information, please contact
digitalcommons@bard.edu.

Investigating the binding potential and downstream effects of
ferrocene/ruthenium(III) complexes with RNA

Senior Project Submitted to
The Division of Science, Math and Computing
of Bard College

by
Mildred Apollo Kissai

Annandale-on-Hudson, New York
May 2015

Table of Contents
PAGE
Abstract ......................................................................................................................i
Dedication................................................................................................................. ii
Acknowledgments .................................................................................................. iii
List of Tables and Figures ........................................................................................ iv

CHAPTERS
1 – Introduction ................................................................................................... 1-20
2 – Materials and Methods ................................................................................ 21-29
3 – Results ......................................................................................................... 30-48
4 – Discussion.................................................................................................... 49-53
5 – References .................................................................................................. 54-57

Vita ....................................................................................................................... 58

i

Abstract
Cisplatin,	
   one of the most popular chemotherapeutic drugs on the market today, battles
cancer by binding to DNA, and causing kinks which obstruct DNA replication and transcription.
As a result, cisplatin halts cell proliferation of not only fast-dividing cancerous cells but healthy
cells as well. To circumvent the shortcomings of cisplatin, the Anderson lab has synthesized a
class of ruthenium (III)/ ferrocene compounds, named the RuLX series. These new heteromultinuclear complexes may have greater selectivity between cancerous and healthy cells
through a proposed synergistic mechanism of their metal centers. Previous work on these novel
complexes has demonstrated that they interact with DNA and proteins, suggesting that they may
share similar molecular targets as cisplatin. RNA has merged as a new molecular target for metal
therapeutics not only due to its chemical similarity with DNA, but also due to its essential role in
cellular function. Many metallochemotheraputics target RNA as well as other biomolecules in
their mode of action.
The in vitro binding affinity of the RuLX complexes with RNA was investigated using a
504-base RNA encoding the dihydrofolate reductase enzyme. Evidence suggests that RuL2 and
RuL3 have a stronger binding affinity to RNA than RuL1. Moreover, in vitro translation of the
DHFR mRNA was carried out to observe the potential downstream effects of these interactions.
All three complexes exhibited a dose-dependent reduction of DHFR enzyme activity.
Investigations with RuL2 specifically, suggest that its inhibition of DHFR activity is likely due
to the metal complex binding to RNA. Explorative controls show that RuL2 does not
significantly inhibit enzyme activity or ribosomal protein activity.
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1. Introduction
1.1 Cancer
Cancer, one of the leading causes of death worldwide, is characterized by uncontrolled
cellular proliferation and avoidance of programmed cell death, or apoptosis1. According to
Hanahan and Weinberg, cancer can be categorized by monitoring the hallmark differences that
cancerous cells develop in comparison to healthy cells. Cancerous cells develop an extensive list
of capabilities that enable their survival and proliferation throughout an organism. These
acquired capabilities include the ability to be self-sufficient in the production and utilization of
growth signals, an insensitivity to antigrowth signals, a cunning evasion of apoptosis, an almost
limitless replicative potential, a sustained ability to form new blood vessels from old ones
(angiogenesis), an ability to invade new tissues, and metastasis2. Cancer malignancy begins
when cancerous cells gain the potential to metastasize, spreading to distant areas of the body
through the circulatory and lymphatic system2. Cancerous cell’s ability to invade surrounding
tissue, colonize, and destroy other tissues throughout the body has been tied to their cellular
motility3. Due to robust research in the field, additional enabling traits that help cancer cells
survive have been stipulated. These traits include the reprogramming of energy harvesting
mechanisms to require low oxygen intake, the ability of cancerous cells to evade destruction
from the immune system, and the development of tumor-promoting inflammation4. The
discoveries of these additional mechanisms that aid in cancer malignancy have been the focus of
current anti-cancer therapeutic research.
Cancer arises as a result of somatic mutations in which genes that become mutationally
under-expressed or abnormally overexpressed contribute to tumor formation, and are called
protoconcogenes5. Moreover, healthy cells can become cancerous through spontaneous or
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inherited mutations in tumor suppressor genes, which are genetic suppressors of tumor growth,
mutations in oncogenes, which are genes that have the potential to promote cancerous growth, or
other somatic mutations that give rise to oncogenes5.
Cancers come in diverse physiological and chemical make-up. Fittingly, different modes of
treating the disease have been developed. Some of the commonly used treatments in human
cancers include: surgery, radiation therapy, immunotherapy, stem cell transplants and
chemotherapy6. First, surgery combats cancer by excising the malignancy out of the body; it
is particularly good at combating benign (non-metastasized) cancerous growth6. Second,
radiation therapy uses high-energy radiation to target and destroy cancer cells6. Radiation
therapy is one of the most common methods of cancer treatment out there today6. Third,
immunotherapy, one of the lesser common cancer treatment methods, involves stimulating the
immune system to work more efficiently in destroying cancer cells6. It may also involve
supplying the immune system with synthesized proteins to stimulate anticancer activity6. Fourth,
stem cell transplants entail a full transplantation of a person’s peripheral blood, bone marrow,
and cord blood6. This treatment is particularly useful in combating cancers that affect the
circulatory and lymphatic system6.
Finally, the most widely known treatment method for cancer, chemotherapy, involves the
administration of combinatorial drugs, usually intravenously, to combat the growth and spread of
cancer cells6. Targeted therapy, which involves the use of chemicals more specifically tailored
for cancerous cells in order to lessen the collateral destruction of healthy cells, is also an option
for persons affected with cancer6. All of the aforementioned treatments are often used
synergistically with each other, depending on the particular cancer type, to effectively destroy
the cancerous cells.
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1.2

Chemotherapy complex: Cisplatin

1.2.1 Discovery of cisplatin
Cis-diaminedichloroplatinum(II),

or

cisplatin is a platinum based compound

Cl
Pt

commonly used as a chemotherapy drug. It was
discovered

by,

Barnett

Rosenberg, a

biophysicist at the University of Michigan, who
at the time, was examining the impact of

Cl

NH 3
NH 3

Figure 1: The chemical structure of
cisplatin.

electrical current in cell division of Escherichia coli (E. coli)7,8. Unexpectedly, Rosenberg et al.
found that interaction of the platinum electrodes and the ammonium chloride buffer caused
filamentous growth and the inhibition of cell division in E. coli7.8. Since the platinum species
proved to be potent in inhibiting bacterial cell division, it was reasoned that the platinum species
might offer similar antiproliferation mechanisms when tested on rapidly dividing cancerous cells.
In order to test the anticancer potential of their platinum species, Rosenberg et al. tested cisplatin,
and ten other group 10 transition metal complexes, on small solid sarcoma 180 tumors in mice8,9.
They found that cisplatin, and some analogs, completely inhibited the development of tumor
growth if administered one day after tumor inoculation in mice. It also yielded impressive
results when it was tested on different cancer types using different animal models9. Cisplatin's
effectiveness in combatting cancer led the FDA to approve it for clinical applications in 197810.
Cisplatin is so potent in combatting cancer that it still boasts a greater than ninety percent cure
rate for promptly diagnosed testicular cancer10.

1.2.2 Cisplatin’s mechanism of action
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Much of cisplatin’s possible mechanisms of action have been elucidated after its clinical
approval due to the emergence of metallochemotherapeutic research. Cisplatin primarily enters
the cell through passive diffusion and active transport mediated by the transporter protein
Ctr1p10,13. The low intracellular chlorine ion concentration of the physiological environment
facilitates the hydrolysis and activation of the cisplatin complex into its aquatic form,
[Pt(NH3)2Cl(OH)2]+ and [Pt(NH3)2(OH2)2]2+ 10. In its active form, cisplatin can react easily with
cellular components such as DNA, RNA, proteins and membrane phospholipids13. Although
cisplatin can react with many cellular components, DNA is believed to be its primary target.
Cisplatin binds to DNA by forming inter-strand and intra-strand adducts with the N7 atom of
purine bases11.

Figure 2: Mechanism of action of cisplatin anti-cancer activity by binding with DNA12
In the aquated form of cisplatin, the weakly bound hydroxide ligand is easily displaced,
allowing the platinum center to coordinate to the N7 nitrogen of the purine bases and form
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covalent bonds11. This results in primarily 1,2 or 1,3-intrastrand crosslinks and a lower number
of inter-strand crosslinks11. The major adducts formed from cisplatin binding are GpG (40-50%)
and ApG (23-38%) intrastrand crosslinks as well as interstrand crosslinks accounting for 1-7% of
adduct formation14. The N7 nitrogen is the most accessible atom for cisplatin coordination
because it is not only located in the major groove of the DNA helix, but it also possesses a lone
pair available for coordination. Once bonded, cisplatin causes a major structural distortion of the
DNA double helix, disrupts base pairing, and widens the minor groove. Cisplatin binding
produces a rigid bend in DNA of 30-35° directed toward the major groove and a localized
unwinding of the DNA helix of 13° 14. As a result, essential biological functions including DNA
repair, replication and transcription are inhibited15. The Pt-DNA adducts additionally activate
several signal transduction pathways including ART, p53, p73 and MAPK which consequently
activate apoptosis15. Sometimes, cisplatin damaged DNA elicits cellular repair mechanisms. If
these repairs are unsuccessful, apoptosis is activated to terminate the cell. Cisplatin has also been
shown to hinder mRNA from directing in vitro peptide synthesis by preventing the formation of
the complete translation initiation complex16, 17. Nevertheless, it is cisplatin’s binding to DNA
that is credited as the mode of action due to which the proliferation of cells is inhibited.

1.2.3 Cisplatin’s shortcomings
Although cisplatin can boast great clinical success, it does come with some potent
drawbacks. One of which is the unselective cytotoxicity that cisplatin bears to both healthy and
cancerous cells which causes severe side effects10. These include damage to nearby convoluted
tubes of the kidney, extreme nausea and intense vomiting9. Moreover, although it was expected
for some tissues to bear spontaneous resistance to cisplatin, recent research has revealed that
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tissues can develop cisplatin resistance over time. The mechanisms by which cells resist
cisplatin-induced cytotoxicity include reduced cellular uptake of cisplatin, the ability to
chemically inactivate the compound and DNA adduct repair18. Reduced cisplatin accumulation
in resistant cells is due to an inhibition in cellular uptake or an increase in drug efflux, or both18.
The inactivation of cisplatin has been attributed to the non-enzymatic and rate-limiting
interactions between aquated cisplatin and endogenous nucleophiles such as glutathione,
methionine, metallothionein and several proteins18. DNA adduct repair via the nucleotide
excision repair mechanism reduces the number of Pt-DNA adducts and as a result, reduces the
cascading of the apoptotic signal18. Furthermore, cisplatin is not active against all primary
tumors. Notable exceptions include breast cancer, prostate cancer and colorectal cancers20. It is
also minimally effective in combatting metastatic cancer due to its mostly cytotoxic mechanism
of action20. As cancers become more resistant to common chemotherapeutic drugs like cisplatin,
and other platinum centered drugs, a focus in biomedical research has centered on developing
new organometallic complexes to circumvent the shortcomings of cisplatin.

1.3 Ruthenium complexes
1.3.1 Prodrug selectivity
In organometallic research, ruthenium complexes have gained popularity as potential
chemotherapeutics due to their unique reactivity. Ruthenium (III) complexes modeled after
cisplatin have demonstrated antitumor properties and lower cytotoxicity than cisplatin. The
octahedral geometry of ruthenium (II) and (III) complexes, as opposed to the square planar
geometry of cisplatin, lends evidence to the hypothesis that ruthenium complexes function
differently from platinum complexes21. For instance, while adjacent intra-strand G-G crosslinks
with cis-Ruthenium ions are possible, they are sterically more hindered due to its octahedral
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geometry21. Moreover, research suggests that Ru (III) complexes function as a prodrug and work
by ‘activation by reduction’ mechanism. Ru (III) complexes are activated by their in
vivo reduction into the chemically active Ru (II) in order to more effectively coordinate to
biomolecules21. The lower charge and the reduced π-bonding effects of Ru (II) that make Ru (II)
more reactive than Ru(III) 21. Moreover, the hypoxic and acidic microenvironment of tumor cells
caused by excess lactic acid creates a low electrochemical potential inside the cell that allows for
Ru(III) to be reduced to Ru(II) selectively in tumor tissue21. Lactic acid accumulation comes
about due to low intracellular oxygen content, which is caused by the lag between the rate of
angiogenesis and the rate of cell growth and division2. As the rate of cancerous cell division
increases, this causes a build-up of tumor tissue that is ineffectively vascularized and as a result,
hypoxic. Until the rate of angiogenesis catches up to the rate of cancerous cell growth and
division, the tumor tissue microenvironment remains hypoxic13. Hence, the higher Ru(II)
compared to Ru(III) concentration in cancerous cells coupled with the inherently higher
reactivity of Ru(II) is thought to make ruthenium based prodrugs somewhat more selective
towards cancerous cells.

1.3.2 New Anti-tumor Metastasis Inhibitor (NAMI) and its analog NAMI-A
Early ruthenium anticancer compounds, which included: cis- and trans-[RuCl(DMSO)]
complexes, paved the way for the design of current clinically used ruthenium based prodrugs
like Na{trans-[Cl4(DMSO)(Im)Ru]}, known as NAMI

and its analog, Na{trans-

Cl4(DMSO)(Im)Ru]}, also known as NAMI-A22. Because these ruthenium complexes can lose
both their chloride and DMSO ligands, the mode with which they bind to biomolecules is more
flexible than cisplatin23. Heterocyclic additions, such as imidazole and indazole, to ruthenium-
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based drugs have also shown to have positive impacts on their anti-proliferation properties19.
NAMI is active against a broad range of tumors including Lewis lung carcinoma, B16
melanoma, and MCa mammary carcinoma23. Notably, research has found that only a very low
fraction of the NAMI reaches the tumor target23. In addition, its activity appears to be
independent of its concentration in tumor cells, and its major mechanism of action does not
involve DNA binding23.
Rather than cytotoxicity, NAMI combats cancer by increasing the resistance to the
formation of tumor metastases. It accomplishes this without enhanced antigenicity or instigating
immunological responses23. NAMI is also credited with down regulating type-IV collagenolytic
activity and metastatic potential of MCa mammary carcinoma. NAMI significantly increases the
mRNAs of MMP-2, a metalloproteinase capable of degrading the extracellular matrix, and
TIMP-2, the specific tissue inhibitor of the aforementioned enzyme at dosages that prevent
metastasis in lung cancer23. This causes a pronounced increase of extracellular matrix
components in the tumor parenchyma and around tumor blood vessels; excess extracellular
matrix components are thought to hinder both metastasis formation and blood flow to the
tumor23.
NAMI-A, a chemical analog of NAMI

H
N

HN

where the sodium counter-ion is replaced with an
imidazolium

ion,

also

boasts

antimetastatic

properties. In vitro, NAMI-A has comparable
binding affinity to DNA as cisplatin24. However,

Cl
Cl

N
Ru
S

Cl

NH

Cl
O

in vivo studies using four different tumor cell lines
revealed that NAMI-A has a much lower affinity

Figure 3:Chemical structure of
NAMI-A
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to DNA than cisplatin24. NAMI-A-induced DNA kinks were only detected at extremely high
dosages compared to cisplatin. Moreover, the frequency of NAMI-A's Ru-GG and Ru-AG
intrastrand adducts to DNA are meek compared to the more plentiful cisplatin intrastrand
adducts25. It is unsurprising that the lower rate of NAMI-A's cellular cytotoxicity was attributed
to its lower intrastrand adduct formation24. However, NAMI-A is capable not only of preventing
the formation of tumor metastases but also, of inhibiting their growth in a similar fashion to
NAMI.

1.4 Ferrocene complexes
Another class of metal complexes that have been shown
to exhibit antineoplastic effects are iron-containing compounds.
In particular, ferrocene−a compound containing two π-bonded	
  
cyclopentadienyl ligands on an iron molecule. This compound’s

Fe

medicinal properties were first investigated because it was the
first iron-containing compound found to exhibit antiproliferative
27

properties . Ferrocene complexes differ from platinum or

Figure 4: The
ferrocene
chemical structure of
ferroccene.

ruthenium complexes in three major ways. Firstly, the central
iron atom exists in the oxidation state +2 in ferrocene and the oxidation state +3 in ferrocenium
ions28. Secondly, they lack any cis-halide ligands able to be dissociated24. Thirdly, they contain
two cyclopentadienyl rings in a sandwiched arrangement; the central iron is tightly bound and is
unlikely participate in further coordination bonds28.
Moreover, ferrocene bears little cytotoxicity. In murine model experiments, it was shown
that orally administered ferrocene is not only non-toxic, but it is degraded (enzymatically
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hydroxylated) in the liver and excreted in urine11. Ferrocene can additionally undergo a oneelectron oxidation to give the ferrocenium cation. This cation is easily soluble due to its salt-like
qualities. It is also relatively stable and the redox reaction from which it was generated is also
reversible11. The ferrocenium salt-like cations exhibited antineoplastic activity against Ehrlich
ascites tumor (EAT) cell lines in CF1 mice, which are very resistant to classical antitumor agents
such as platinum centered metal complexes27. While they found that the ferrocene complex itself
bears no recognizable antitumor effects on these cells lines, they found that ferrocenium salt-like
complexes boast incredible inhibitory effects, with some 100% cure rates of tumors27. Other
ferrocene derivatives have shown significant anticancer potential, for instance that of tamoxifen
and its derivatives. Tamoxifen is the front-line chemotherapeutic agent for patients with
hormone-dependent breast cancer. Its active metabolite is hydrotamixifen. Tamoxifen combats
breast cancer by competitively binding to the ERα subtype and repressing estradiol-mediated
DNA transcription in the tumor tissue11.

A)

H

B)

OH

	
  

Fe

Fe
O(CH2)2N(CH 3)2

O(CH2)2N(CH 3)2

Figure 5: The chemical structure of A) Ferrotamoxifen and B) Ferro-hydrotamoxifen.11
Although the mechanism of action of these ferrocenium salts has yet to be elucidated, it is
proposed that their cytotoxic activity is not based on their direct linking to DNA, but rather
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on their ability to generate oxygen active species that induce oxidative DNA damage24. It is
thought that ferrocenium cations generate hydroxyl radicals in physiological conditions that
damage DNA via fenton-type reactions28. The tumor microenvironment, which contains
increased concentrations of hydrogen peroxide, allows for the production of these radicals.
Un-substituted ferrocene is insoluble in water; it is unsurprising that it does not display
any tumor inhibiting activity. However, once inserted into the target cells, it could interconvert to
the ferrocenium cation, and vice versa, depending upon the redox potential of the tumor
microenvironment28. Hence, much like the ruthenium containing complexes, ferrocenium salts
have the potential to selective target cancerous cells while causing little harm to healthy cells.

1.5 Multinuclear compounds
To circumvent cellular resistance to cisplatin, multiplatinum complexes modeled after
cisplatin were developed14. These complexes bound to DNA in a similar manner to cisplatin.
However, due to their larger size and varied ligands, these multiplatinum complexes were able to
form non-directional DNA adducts, to form a greater number of interstrand adducts compared to
cisplatin, and to induce conformational type changes to both A- and Z-type DNA14. It has been
suggested that DNA repair proteins weakly recognize DNA adducts resultant from multiplatinum
complexes because of their different characteristics compared to cisplatin induced DNA adducts.
Consequently, the structural changes caused by multiplatinum complexes bypass recognition
from DNA repair proteins and more successfully, inhibit DNA transcription and replication14.
Moreover, due to the discovered anticancer potential of different transition metal
complexes, recent research has sought to combine different metal centers into one complex that
would posses the best qualities of all its components. Some mixed-metal species that has
afforded some success in heteromultinuclear antineoplastic research are a series of complexes
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that couple a light absorbing ruthenium (II) or osmium (II) metal center to a reactive platinum
site that contains the cis-dichloride platinum moiety. This moiety is through to be responsible for
cisplatin’s anticancer activity

29-31

. Brewer and colleagues found that their novel complexes

awarded a higher percentage of interstrand crosslinks compared to cisplatin. Furthermore,
tridentate bridged Ru(II)-Pt(II) and tetrametallic multinuclear complexes were also found to have
more robust chemical interactions with DNA than cisplatin29- 31. Multinuclear complexes have
the potential to exhibit synergistic effects that may result in a greater impact on their target
biological system than their mononuclear counterparts32
Anderson et al. have developed
2

several heteromultinuclear complexes
containing both ruthenium and platinum
centers

that

antineoplastic

have
and

demonstrated

S

Cl
Ru

Cl

Cl
N Pt
N

N

Cl

(II)

Cl
2 Na

anti-metastatic

potential32, 33. Na2 {trans, cis, trans- [Ru
(III)

Cl

O

N
Cl

Ru

Cl

Cl
Cl

Cl4(DMSO-S)(-µ-pyz)]2Pt Cl2},
O

S

otherwise known as AH197, a trinuclear
complex with characteristics of both

Figure 6: The chemical structure of AH19725

NAMI and cisplatin, was shown to bind DNA with better efficacy than cisplatin33. The complex
also demonstrated greater inhibition of cell proliferation, using a S. cervasie model system, than
both NAMI-A and cisplatin32. Moreover, AH197 appears to be more cytotoxic than cisplatin and
KP1019−another ruthenium centered anticancer compound, in leukemia (CCRF-CEM), NSC
lung, breast (BT-549), and colon (COLO 205) cancer cell lines33. Although its mechanism of
action has not been elucidated, it appears that AH197 binds RNA and terminates primer
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extension in in vitro reverse transcription assays by generally inhibiting DNA polymerization34.
This suggests that AH197 targets nucleic acids much like cisplatin.
The Anderson lab also synthesized another
compound, [K][RuIIICl4 (DMSO)(-µ-pyz)-PtII(DMSOS)Cl2], also known as IT127, a dinuclear complex which
showed similar anticancer potential32. IT127 also has the

O

S
Cl Pt Cl
N
N

ability to inhibit cell motility at a degree comparable to
NAMI-A32. Moreover, electrophoretic mobility shift
assays demonstrated that IT127 has a higher binding
affinity for plasmid DNA than both cisplatin and
AH19732. This suggests that this hetero-multinuclear
complex may target the nucleic acids, much like

Na

Cl
Cl

Ru

Cl
Cl

S
O
Figure 7: The chemical
structure of IT12725

cisplatin, but it may inhibit metastasis in a similar manner to NAMI-A.
Recently, the Anderson lab developed a new class of compounds that combine the
structure of NAMI-A with a ferrocene moiety in order to explore potential synergistic effects
from the combination of two anti-proliferation compounds35. Hoping to combine their low
cytotoxicity and potential selectivity for cancerous cells, these new compounds may provide
increased DNA damage through the ferrocenium salts and antimetastatic qualities from the
NAMI-A component of the compounds. By combining the therapeutic effects of these two
complexes into one complex, cancer cells could be more selectively targeted and aptly combated
with reduced side effects. Three complexes were synthesized, [Na][trans-RuCl4(dmso)(pyrdylferrocene)], [Na][trans-RuCl4(dmso)(imidazolyl-ferrocene)], and [Na][trans-RuCl4(dmso)(4 –
ferrocenoyl-pyridine)] which will be referred to as RuL1, RuL2 and RuL3 respectively35.
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A)

B)
O

Cl Cl O
N Ru S
Cl Cl
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H

Na

O
O
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N
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N Ru S
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O

C)

O

Cl Cl O
N Ru S
Cl Cl

Na

Fe

Figure 8: The chemical structures of the RuLX series of complexes. A) RuL1 B) RuL2 C)
RuL327
In electrophoretic mobility shift assays, all three compounds exhibited dose-dependent
interactions with plasmid DNA comparable to cisplatin35. Moreover, when incubated with both
human and bovine serum albumin proteins, all three complexes exhibited a dose-dependent
affinity to the proteins visualized in native polyacrylamide gel electrophoresis (unpublished
results). RuL3 in particular exhibited such a strong affinity that it appears to degrade the proteins
after incubation at physiological temperatures36. Moreover, studies monitoring the obscuring of
tryptophan’s fluorescent signal due to RuLX interactions with BSA showed that all three
complexes possess interactions with the BSA proteins35.
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A)
	
  

	
  

RuL3
	
  

RuL2

RuL1

Cisplatin

	
  

B)
	
  

RuL1

	
  

RuL2
	
  

RuL3

Figure 9: A) Agarose (1.5%) gel electrophoresis of cisplatin, RuL1, RuL2, & RuL3 treated
DNA (1 µg) using various concentrations of each drug. The bands were visualized using
ethidium bromide.27 B) 8% Native-PAGE images where Bovine Serum Albumin incubated
with RuL1, RuL2 and RuL3 in increasing concentrations28.
Due to such evidence, the RuLX compounds are fitting candidates to investigate their
binding potential to RNA, which is similar to DNA in chemical structure, and any potential
downstream effects that may arise.

1.6. Translation inhibition as an anticancer target
Translation, the process in which cellular ribosomes build proteins using information
garnered from messenger RNA, is an attractive target for cancer therapy due to its importance in
the cell cycle. The fact that ribosomal subunits can self assemble in vitro from their constituent
parts provided the ability to identify the roles of proteins and their processes during ribosome
assembly and translation37. Protein synthesis takes place following assembly of both the 40S and
60S subunits onto the mRNA, and given the presence of charged tRNAs. The process of protein
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synthesis goes as follows: Firstly, synthesis proceeds from the N-terminus to the C-terminus of
the protein37. Secondly, the ribosomes read the mRNA in the 5' to 3' direction. Thirdly, active
translation occurs on polyribosomes. This means that more than one ribosome can be bound to
and translate a given mRNA at any one time37. Finally, chain elongation occurs by sequential
addition of amino acids to the C-terminal end of the ribosome bound polypeptide. Translation
proceeds in an ordered process37. First, accurate and efficient initiation must first occur, only
then can chain elongation take place and finally, accurate and efficient termination is required to
finish the job37.
The initiation of translation occurs in four specific steps: first, ribosome must dissociate
into its 40S and 60S subunits. Several initiation factors (e.g. eukaryotic translation initiation
factor-1 [eIF-1] and eIF-3) are required to ensure that the 60S and 40S ribosomal subunits remain
separated so that new rounds of translation can begin37. Then, the ternary complex−composed of
GTP bound to the α-subunit of eIF2 and the initiator methionyl-tRNAmet, forms and engages the
40S subunit37. The eIF-4F complex−the mRNA activator for translation, which comprises the
cap-binding factor, eIF-4E, the RNA helicase eIF-4A, and the scaffold subunit eIF-4G, captures
mRNA and brings it to the 40S subunit and the ternary complex37. The mRNA then binds to the
ternary complex and the 60S subunit associates with the pre-initiation complex to form the 80S,
subunit thus completing of the process of translation initiation37. This key step in translation is an
attractive anti-proliferative target as proteins synthesis cannot take place without it correct
completion. Moreover, the plethora of proteins that are required to modulate this process
provides ample targets for this task.

17

Figure 10: Protein complexes
in the formation of a
eukaryotic initiation complex.
The 3’and 5’ ends of
eukaryotic mRNAs are linked
by a complex of proteins that
includes several initiation
factors and the poly(A) binding
protein (PAB). The factors
eIF4E and eIF4G are part of a
larger complex called eIF4F
that binds to the 40S ribosomal
subunit. 37

One of the most recent targeted proteins for anti-proliferative properties is the eukaryotic
translation initiation factor 4E (eIF4-E). EIF4-E is frequently overexpressed in human cancers
when examined in relation to disease progression38. Its overexpression also drives cellular
transformation, tumorigenesis, and metastatic progression in experimental models. Enhanced
eIF4E function can be caused by eIF4E overexpression, and/or activation of the ras and
phosphatidylinositol 3-kinase/AKT pathways38. This selectively increases the translation of key
mRNAs involved in tumor growth, angiogenesis, and cell survival. Consequently, targeting
eIF4E for inhibition may provide an attractive therapy for many different tumor types38. This is
because reducing eIF4E expression simultaneously and selectively reduces the expression of
other growth and survival factors critical for malignancy38.

1.7. Silvestrol: a translation inhibiting anticancer compound
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Figure 11: The chemical structure of Silvestrol

amount of research has been conducted targeting translation initiation inhibition as anti-cancer
therapy. It was additionally found that eIF4E cooperates with c-Myc during lymphomagenesis to
induce drug resistance, and is a genetic modifier of the rapamycin response39. The effect of
dysregulation of the ribosome recruitment phase of translation initiation was also found to affect
tumor progression and chemosensitivity39. A candidate drug, Silvestrol, a compound in a class of
natural cyclopenta[b]benzofuran flavaglines was shown to enhance chemosensitivity in a mouse
lymphoma model in which carcinogenesis is driven by phosphatase and tensin homolog (PTEN)
inactivation or elevated eIF4E levels39. These results establish that targeting translation initiation
could restore drug sensitivity in vivo and provide an approach to modulating chemosensitivity39.
It was also shown that silvestrol is a potent anticancer compound in vivo as it inhibits the
translation of malignancy-related mRNAs, affecting survival pathways and angiogenesis40.
Silvestrol’s mechanism of action is said to be that it promotes the dimerization of eIF4A with
RNA, which disrupts efficient translation initiation40. This, in turn, inhibits protein synthesis and
as a result, disrupts tumor survival pathways.
The potential of heteromultinuclear metal complexes to inhibit translation inhibition has
seldom been discussed in recent research. The unselective nature of reactivity of metal
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complexes with biomolecules makes metal complexes an attractive class of complexes to be
studied for this purpose. Cisplatin has been implicated in in vitro translation inhibition by
preventing the formation of the complete initiation complex and perhaps slowing down the
process of chain elongation during translation17. The RuLX series of compounds have shown an
affinity to bind both DNA and proteins, which begs the question: Do these complexes interact
with RNA? If so, would this interaction interfere with the process of translation?

1.8. Experimental overview
To investigate the potential binding and inhibitory effects of the RuLX series of
compounds, a model system using dihydrofolate reductase (DHFR) plasmid DNA was
employed. DHFR plasmid was chosen not only due to its convenience−it is the control DNA
provided by New England Bio labs Pure Express® In Vitro Protein Synthesis kit, but also due to
that fact that it contained all the necessary information to be transcribed into RNA and translated
into a detectable DHFR enzyme. Once acquired, the plasmid DNA will be amplified and
digested in preparation for its transcription into RNA. Following transcription, the binding
affinity of RuLX series of compounds to the resultant DHFR RNA will be investigated using an
electrophoretic mobility shift (EMSA) assay. The EMSA assay is based on the observation that
in agarose gel electrophoresis, heavier items migrate more slowly through the gel than lighter
items. Thus, RNA successfully bound to any of the RuLX series of compounds will migrate
more slowly than unbound RNA and difference in electrophoretic mobility would be evident.
Moreover, this interaction should be evident in a dose-dependent manner as the greater the
concentration of bound drug there is, the slower RNA migration.
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Furthermore, downstream effects of RuLX-bound RNA will be investigated by
comparing the translation efficiencies of DHFR RNA unexposed to the RuLX series of
compounds versus the DHFR RNA that was exposed. Product presence will be detected using a
DHFR assay that monitors the disappearance of NADPH, which has unique UV absorbance at
340 nm. DHFR catalyzes the reduction of 7,8-dihydrofolate to 5,6,7,8-tetrahydrofolate utilizing
NADPH as a cofactor.
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Figure 12: The reaction catalyzed by the enzyme dihydrofolate reductase using NADPH as its
coenzyme.
Interestingly, within cells, this reaction is an essential step in the biosynthesis of
nucleotide bases of DNA41. DHFR has also been considered as a target for anticancer drugs
because its blockage in the cells causes apoptosis as a consequence of DNA synthesis
inhibition41-43. Nevertheless, if exposure to the RuLX series of compounds prior to translation
results in a reduction of DHFR activity, it is likely that the RuLX series of compounds can
inhibit translation, at least in vitro. The RuLX series of complexes possess similar interactions
with nucleic acids as ferrocenium salts and cisplatin. Hence, it is possible that they may also
inhibit the in vitro translation of DHFR enzyme by binding to its mRNA.
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2. Materials and Methods
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production using RuLX-incubated
translation machinery
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Quantification of DHFR activity
using RuLX incubated with pure
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Follow-up studies: Inhibition of in vitro
translation due to RuLX-RNA interactions
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2.2.

Transformation of Dihydrofolate Reductase (DHFR) plasmid into

competent Escherichia Coli cells
Zymo® Mix & Go competent cells were thawed on ice and 2 µL of Dihydrofolate
Reductase plasmid acquired from New England Bio labs Pure Express® In Vitro protein
synthesis kit was added to the competent cells. After mixing gently for a few seconds 50 µL of
the mixture was spread onto a pre-warmed (37°C) LB culture plate containing Ampicillin (100
µg/mL). The plate was incubated at 37°C overnight. A colony was harvested from the plate and
grown, as a starter culture, on 5 mL of LB liquid media also containing Ampicillin (100 µg/mL)
overnight to prepare for plasmid extraction. Starter culture was diluted 1/1000 into 200 mL of
LB ampicillin (100µg/mL) containing liquid culture. The mixture was grown at 37°C for 16
hours shaking at 220 rpm.

2.3. Plasmid Extraction of DHFR plasmid using QIAGEN Plasmid Maxi Prep
Kit44
Plasmid extraction was performed according to QIAGEN instructions with the following
modifications44. The starter culture was shaken at 220 rpm instead of the recommended 300 rpm.
The 7th Centrifugation step was conducted for 1 hour at 4 °C, instead of the suggested 30
minutes. The DNA was precipitated using ice-cold 100% ethanol instead of isopropanol and
centrifuged as indicated by the QIAGEN maxi prep instructions.

2.4.

Restriction Digestion (RD) of 10 µg of DHFR plasmid using the

restriction enzymes
Table 1: Reaction Assembly of restriction digestion of 10 µg of DHFR plasmid

DHFR plasmid (0.359 µg/µL)

Volume (µL)
28

23
10X NEB Buffer # 2
10 U BamH1or StuI enzyme (5 U/µL)
DEPC-treated H2O
Total Reaction Volume

5
2
15
50

The above contents were thawed on ice, assembled in a fresh microcentrifuge tube,
mixed thoroughly, and spun down to the bottom of the tube. After which, they were incubated at
37°C for 5 hours. The reaction products were purified using phenol chloroform extraction
followed by ethanol precipitation.
Phenol: Chloroform Extraction was conducted as follows. One volume of Phenol:
Chloroform: Isoamyl Alcohol (25:24:1) from Ambion was added to the restriction digestion
product (50 µL). The mixture was vortexed for 30 seconds and then centrifuged for 2 minutes at
14000 rpm (top speed) 20° C. After, the upper, aqueous phase of the mixture was extracted and
placed in a new microcentrifuge tube where one more volume of phenol: chloroform: isoamyl
alcohol was added. It was vortexed for one minute and spun at top speed, 20°C for 2 minutes.
Then, the upper, aqueous phase was, once again, transferred to a fresh tube. Any transferred
chloroform was removed by centrifugation for 10 seconds at top speed followed by removal of
the bottom phase with a micropipette. The resultant RNA solution was precipitated using ethanol
precipitation.
Ethanol precipitation was conducted as follows. 1/10th of reaction volume of 3 M sodium
acetate (NaOAc) was added to the mixture (for a final concentration of 0.3M NaOAc) and
mixed thoroughly. Then, three volumes of 100% ethanol was added to the resultant mixture and
mixed thoroughly. The mixture was placed in -80°C freezer for 1 hour (to overnight) prior to
centrifugation. The resultant microcentrifuge tube was centrifuged at 14000 rpm, 4°C for 1 hour
and its supernatant was discarded and the pellet was washed with 70% ethanol. After the 70%
ethanol was discarded the tube was air dried for 10-20 minutes and then re-suspended in 30µL
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TE buffer. A 1:25 dilution was made in TE buffer for UV quantification of RD product and a
diagnostic 1% agarose gel comparing circular DHFR DNA and linearized DHFR product was
also prepared to ensure proper linearization.

2.5.

In Vitro Transcription (TXN) of DHFR DNA
Table 2: Reaction assembly of a preparative scale in vitro transcription of DHFR DNA
Amount (µL)
10
10

DEPC H2O
10X Transcription Buffer (400 mM TrisHCl, 60 mM MgCl2.6H2O, 100mM DTT)
10X (25 mM) Ribonucleotides
10
Linear DNA template (0. 976 µg/µL, 1.08
10
µM)
Inorganic Pyrophosphatase (0.1 U/µL)
5
T7 RNA Polymerase
25
TOTAL
100 µL
The above ingredients were thawed on ice and assembled, as written, at room
temperature and in a new microcentrifuge tube; the mixture was then incubated at 37 °C for 3
hours.10U of TURBO DNase was then added to the mixture and incubated at 37°C for an
additional 30 minutes. To stop the reaction, 5 µL of 500mM EDTA was added to the mixture
The mixture was then purified using phenol: cholorform: isoamyl alcohol and precipitated using
ethanol as aforementioned in the previous section.

2.6.

Preparative incubation of RNA with RuLX complexes

Table 3: Reaction assembly of preparative scale incubations of RuLX with RNA
RNA (µg/µL)
RuLX

0 µM
10 µL
----

TE Buffer
TOTAL

10 µL
20 µL

5 µM
10 µL
✪
2 µL
8 µL
20 µL

50 µM
10 µL
2 µL¤
8 µL
20 µL

250 µM
10 µL
1 µL¢
9 µL
20 µL

500 µM
10 µL
2 µL¢
8 µL
20 µL

25
¢ From 5 mM Stock RuLX
¤ From 0.5 mM Stock RuLX
✪ From 0.05 mM Stock RuLX
The above materials were incubated at 37°C for 3 hours . After incubation, the mixtures
were aliquoted (4 aliquots of 2 µL each, 2 aliquots of 6 µL) for future translation and stored in 80° C freezer.

2.7.

Binding studies of RuLX complexes with DHFR RNA using an
electrophoretic mobility shift assay
1-1.3% agarose gels were prepared where previously incubated samples (6 µL aliquots)

were run using Bio-Rad’s Sub-Cell® agarose gel electrophoresis systems at appropriate voltages.

2.8.

In Vitro Translation (TSN) of DHFR plasmid

Table 4: Reaction assembly of a representative in vitro translation (TSN)
Control DNA
Solution A
Solution B
Nuclease-free H2O
Template RNA
TOTAL

5 µL
3.75 µL
2.75 µL
1 µL
12.5 µL

No
Reaction
5 µL
3.75 µL
3.75 µL
0 µL
12.5 µL

TSN
5 µL
3.75 µL
2.75 µL
1 µL
12.5 µL

The mixture was assembled as written and incubated at 37°C for 3 hours. After
incubation the mixture was stored in -21°C freezer until the DHFR activity assay was conducted

2.9.

Detection of translation product: DHFR activity assay45

The assay was conducted following Sigma-Aldrich’s DHFR assay kit using the following
schemes and subsequent specifications:
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Table 5: Reaction schemes followed when using the DHFR assay
Reaction

Dihydrofolic
NADPH
Acid
(µL)
(µL)
10 µL
6
-----10 µL
----5
10 µL (0.040 mg/mL) of
6
5
DHFR enzyme
6 µL of translation product
6
5
without nucleic acid input
6 µL of translation product
6
5
resulting from DHFR plasmid
6 µL of translation product
6
5
resulting from DHFR mRNA

Assay Buffer 1x Sample
(µL)

Blank I
Blank II
DHFR
enzyme

984
985

‘No RXN’

981

‘Control
DNA’

981

‘TSN3’

981

979

The Cary UV spectrophotometer was set to collect a scan ranging from 290 nm to 410
nm, approximately every 25 seconds for five minutes. The reaction was set at 22°C using the
block temperature control.

2.10. Survey of translation inhibition: RNA and RuLX Translation Inhibition
Studies
Table 5: Reaction assembly of in vitro translations used in the survey of translation inhibition:
Solution A
Solution B
Nuclease-free H2O
Template RNARuLX
TOTAL

0 µM
5 µL
3.75 µL
1.75 µL
2 µL

5 µM
5 µL
3.75 µL
1.75 µL
2 µL

50 µM
5 µL
3.75 µL
1.75 µL
2 µL

250 µM
5 µL
3.75 µL
1.75 µL
2 µL

500 µM
5 µL
3.75 µL
1.75 µL
2 µL

12.5 µL

12.5 µL

12.5 µL

12.5 µL

12.5 µL

The mixture was assembled as written above and incubated at 37°C for 3 hours. After
incubation the mixture was stored in -21°C freezer until ready to use in DHFR assay. A DHFR
assay of resultant translation products of RNA-RuLX complexes was conducted using SigmaAldrich Corp’s45 protocol using the following reaction schemes and subsequent changes:
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Table 6: Reaction Schemes used in the survey of translation inhibition
Reaction
0 µM
5 µM
50 µM
250 µM
500 µM

Assay Buffer 1x
(µL)
981
981
981
981
981

Translation Product
(µL)
6
6
6
6
6

NADPH
(µL)
6
6
6
6
6

Dihydrofolic Acid
(µL)
5
5
5
5
5

Initial studies were conducted where the Cary UV spectrophotometer was set to collect a
scan ranging from 290 nm to 410 nm, approximately every 25 seconds for five minutes. The
reaction was set at 22°C using the block temperature control. Subsequent studies were conducted
where Cary UV spectrophotometer was set to collect the absorbance at 340 nm approximately
every 12 seconds for five minutes. The reaction was set at 22°C using the block temperature
control.

2.11. Important Controls I: Quantification of DHFR production using RuLXincubated translation machinery
Table 7: Reaction assembly for incubation of RuLX complexes with ribosomal proteins
Control (0 µM RuLX)

80 µM RuLX

Solution A
Solution B
Nuclease-free H2O
Template RNA
RuLX

5 µL
5 µL
3.75 µL
3.75 µL
3.75 µL
0.75 µL
1 µL
1 µL
--2 µL
TOTAL
13.5 µL
12.5 µL
The mixture, without RNA, was assembled as written and incubated at 37°C for 3 hours.

After incubation RNA was added to the appropriate samples and set, once more at 37°C for 3
hours. Thereafter, the mixture was stored in -21°C freezer until ready to conduct the DHFR
activity assay. DHFR assay of resultant translation products of RuLX-incubated translation
machinery was conducted using Sigma-Aldrich Corp’s45 protocol using the following reaction
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schemes and subsequent changes:
Table 8: Reaction schemes for DHFR assay of RuLX-treated ribosomal proteins
Reaction (rxn)

Assay Buffer
1x (µL)

Translation product
(µL)

NADPH
(µL)

Dihydrofolic Acid
(µL)

981

6

6

5

981
981
981

6
6
6

6
6
6

5
5
5

Control (0 µM
RuLX)
80 µM RuL1
80 µM RuL2
80 µM RuL3

Initial studies were conducted where the Cary UV spectrophotometer was set to collect a
scan ranging from 290 nm to 410 nm, approximately every 25 seconds for five minutes. The
reaction was set at 22°C using the block temperature control. Subsequent studies were conducted
where the Cary UV spectrophotometer was set to collect the absorbance at 340 nm,
approximately every 12 seconds for five minutes. The reaction was set at 22°C using the block
temperature control.

2.12. Important Controls II: Quantification of DHFR production using RuLX
incubated with pure DHFR enzyme
Table 9: Incubation mixture assembly of RuLX complexes and DHFR enzyme
Pure DHFR (0.40mg/mL)
0.5 mM RuLX solution
DEPC H2O

Control (0 µM RuLX)
6 µL
--9 µL
TOTAL
15 µL

80 µM RuLX
6 µL
2.4 µL
6.6 µL
15 µL

The above mixture was incubated at 37°C for 3 hours. It was then stored in -20°C freezer
overnight until ready for DHFR activity assay. DHFR assay of resultant translation products of
RNA-RuLX complexes was conducted using Sigma-Aldrich Corp’s45 protocol using the
following reaction schemes and subsequent changes.
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Table 10: DHFR reaction scheme for RuLX-treated enzyme
Reaction (rxn)
Control (0 µM
RuLX)
80 µM RuL1
80 µM RuL2
80 µM RuL3

Assay Buffer 1x
(µL)

DHFR
(µL)

NADPH
(µL)

Dihydrofolic Acid
(µL)

974

15

6

5

974
974
974

15
15
15

6
6
6

5
5
5

Initial studies were where the Cary UV spectrophotometer was set to collect a scan
ranging from 290 nm to 410 nm, approximately every 25 seconds for five minutes. The reaction
was set at 22°C using the block temperature control. Subsequent studies were conducted where
the Cary UV spectrophotometer was set to collect the absorbance at 340 nm, approximately
every 12 seconds for five minutes. The reaction was set at 22°C using the block temperature
control.

2.13. Follow-up Studies: Inhibition of in vitro translation due to RuLX-RNA
interactions
Follow-up studies were conducted using RuL2-incubated RNA in 0, 5, 50 and 250 µM
concentrations of the drug. Triplet translations were assembled of each concentration according
to aforementioned specifications (see Materials and Methods 2.110.). DHFR activity was
monitored in likewise fashion. Moreover, a control measuring the effect of RuL2 incubation on
pure DHFR enzyme was also set up in triplicate (see Materials and Methods 2.12.). DHFR
activity was also measured for this set of experiments.
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3. RESULTS
Successful amplification of plasmid DFHR DNA, digestion of said DNA and its in vitro
transcription established the chosen model system as a successful system to investigate
translation inhibition. Evidence suggests that RuL2 and RuL3 have a stronger binding affinity to
RNA than RuL1. Furthermore, all three complexes exhibited a dose-dependent reduction of
DHFR activity. Follow-up studies, with RuL2 specifically, suggest that its inhibition may be due
to binding to RNA, binding to the translation machinery or binding to translation product, the
DHFR enzyme itself. Explorative controls show that RuL2 does not significantly inhibit pure
enzyme activity or ribosomal protein activity. Thus, it is likely that RuL2 interacts with the
mRNA is such a way that it inhibits translation of a full-length, active DHFR enzyme.

3.1. Amplification, digestion and in vitro transcription of DHFR DNA
A)

Extracted DHFR plasmid I

B)

Extracted DHFR plasmid II

Figure 13: Representative graph of UV quantification of dilute (1:25) DHFR plasmid
from E. coli to give the concentrations A) 0.375 µg/µL and B) 0.359 µg/µL. The fractions
gave A260/A280 ratio of A) 1.70 and B) 1.72 respectively.
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Figure 14: Representative agarose gels (1.0%) comparing plasmid DHFR DNA and linearized
DHFR DNA were visualized using ethidium bromide. Both gels were run at 100V for 1 hr. A)
Restriction digestion of 4 µg of plasmid DHFR using BamH1 enzyme. B) Restriction digestion
of 1 µg of plasmid DHFR using StuI enzyme
To determine whether amplification of DHFR plasmid was successful, plasmid was
extracted from transformed E. coli cells and quantified by measuring the solution’s UV
absorbance. It yielded two aliquots of plasmid DNA that are 0.375 µg/ µL and 0.359 µg/µL; the
DNA was relatively pure as both aliquots had A260/A280 ratios of 1.70 and 1.72 respectively – a
small deviation from the ideal A260/A280 of 2 (Figure. 13).
To check the extracted plasmid’s length and to determine success of restriction digestion,
agarose gel electrophoresis of both circular DHFR DNA and the restriction digested DNA was
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conducted. Gel analysis also showed appropriate bands for plasmid DHFR DNA; the band was
near ~3000 base pairs which was congruent with the length of the DHFR plasmid which is 2879
base pairs (Figure. 14). Dense bands evident in the plasmid DNA lane are most likely due to
overloading of the well with DNA and perhaps some of its smearing can be attributed to the
degradation of some of the DNA (Figure. 14A). However, once digested with StuI and purified,
degraded DNA was discarded and the resultant linear DNA showed greater band quality when
run on an agarose gel (Figure. 14). Furthermore, the linearized DNA migrated slightly slower
than the plasmid DNA indicating that it is, in fact, linear (Figure 14B). Plasmid DNA migrates
slower than linear DNA due to the superhelical tension of its confirmation.
2-Log
Ladder

I.

II.

III.

10.0 kb
4.0 kb
3.0 kb
2.0 kb
1.5 kb
1.0 kb
0.6 kb
0.5 kb

Figure 15: Diagnostic agarose gel (1.0%)
visualized using ethidium bromide. Both
gels were run at 100V for 1 hour I. Linear
DHFR DNA, II. Product of In Vitro
Transcription, and III. RNAse A-digested
In Vitro Transcription Product.
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Figure 16: Representative graph of UV detection of 0.667 µg/µL RNA at 260 nm. Its
A260/A280 ratio was 1.89. Samples were diluted 1:25 in DEPC-treated H2O
To determine the success of in vitro transcription, agarose (1%) gel electrophoresis
comparing the linear DHFR DNA to the transcription product and to the transcription product
digested with RNase A was performed. The success of the in vitro transcription was ascertained
due to the fact that the transcription product showed no presence of the DHFR DNA (~3000 base
pairs) when analyzed by agarose gel electrophoresis (Figure 15I, 15II). The presence of a strong
band at ~500 base pairs, congruent with the length of the DHFR mRNA which is 504 bases in
length showed successful transcription of the DHFR mRNA (Figure 15II). Moreover, the
transcription product is successfully digested by RNase A as evidenced by the disappearance of
the band at ~500 base pairs and the presence of digested RNA in lengths shorter than 500 base
pairs (Figure 15III). The mRNA product was detectable by UV and considerably pure with a
A260/A280 ratio of 1.89 (Figure 16).
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3.2. In Vitro Translation and detection of DHFR activity
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Figure 17: The depletion NADPH monitored by observing decay of 340 nm peak. A) Activity
of translation product resultant from control DHFR DNA B) Activity of translation product
without input of nucleic acid C) Activity of translation product resultant from DHFR mRNA
obtained from in vitro transcription.
To determine whether successful translation of DHFR mRNA into an active, full-length
DHFR enzyme occurred, three translation reactions were assembled. Each reaction contained
either plasmid DFHR DNA obtained from the Pure Express® translation kit, 504-base DHFR
mRNA obtained from in-house transcription, or no nucleic acid input. DHFR enzyme production
was measured by monitoring the depletion of NADPH using its distinct absorbance at 340 nm.
The rate of NADPH depletion is used as a quantifying reporter of the presence of full-length,
active DHFR enzyme produced from in vitro translation. The faster the NADPH is consumed in
the assay, the more DHFR enzyme is present in the translation product. A clear reduction in
absorbance at 340 nm is evident from the resultant data (Figure 17). It is important to note that
because proteins absorb at 280 nm, there is an obscuring of the signal at 340 nm by the intense
protein absorbance resulting from not only the DHFR enzyme translated, but also from the
ribosomal proteins responsible for the translation itself. However, the isosbestic points at ~314
nm and ~400 nm describe a two-state process and thus an adequate measure of NADPH
disappearance.
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Figure 18: Baseline corrected UV spectral analysis monitoring the depletion of NADPH using
0.0040 mg/mL DHFR over 3 hours. Baseline reading was obtained from the UV analysis of all
DHFR assay ingredients with the exception of NADPH (See Blank II of Materials and Methods
section 2.9).

Nevertheless, a possible way to combat this obscuring of signal is to record a baseline
correction reading using all the assay components except NADPH. A small sample of DHFR
enzyme when measured using the aforementioned baseline correction, showed a considerable
reduction in obscuring (Figure 18). Unfortunately, this baseline correction proved difficult to
reproduce during subsequent trials, and thus was abandoned. However, because our analysis
requires only the respective initial reaction rates to report the amount of DHFR produced,
observing the depletion in the peak at 340 nm, regardless of obscuring, is still acceptable.
The DHFR mRNA appears to produce less enzyme compared to the DHFR plasmid DNA
provided by the In Vitro Translation Pure Express ® Kit. This is evident in the significant
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decrease in absorbance for the enzyme activity yielded by translating the DNA; it fell from 0.416
to 0.260 absorbance units in 79 seconds. The enzyme activity yielded by translating DHFR
mRNA (obtained via in-house in vitro transcription) fell from 0.684 to 0.671 in the same amount
of time (Figure 17A, Figure 17C). This suggests that there is larger quantity of DHFR enzyme
produced by the translation reaction using DNA provided by the kit. Since the kit can translate
full-length proteins given either DNA or RNA as input, it possesses the ability to conduct both
transcription and translation. It is likely that these processes are coupled48. This produces a
greater quantity of enzyme when DNA is used48. Nonetheless, successful translation of the
DHFR mRNA into the active enzyme indicates that the DHFR assay is still a successful model
system to investigate the process of translation and its inhibition.
Measuring the inability to produce full-length product, using DHFR mRNA as our input,
can be used as a reporting system for investigating translation inhibition. Furthermore, the Pure
Express ® in vitro translation system is an appropriate model system to investigate translation
inhibition due to the fact that none of the ribosomal proteins that compose the translation
machinery consume NADPH when tested in the DHFR assay. This was ascertained by the lack
of change when the ribosomal proteins lacking in nucleic acid input were investigated using the
DHFR assay (Figure 17B). All in all, the DHFR enzyme activity can be used as a reporter of the
amount of DHFR produced by the translation system because not only does Pure Express ® in
vitro translation kit produces active DHFR detectable by a DHFR assay, but also its components
do not consume NADPH.

3.3. Binding studies using electrophoretic mobility shift assay

38

10.0 kb
3.0 kb
2.0 kb
1.5 kb
1.0 kb
0.5 kb

Figure 19: Agarose (1.0%) gel electrophoresis of RuL1, RuL2, & RuL3 treated RNA (3 µg)
with increasing concentrations of each drug: 5, 50, 250, 500 µM. RNA was incubated with
RuLX complexes for 3 hours. Gel was run at 100V for 1 hour.
To determine whether the RuLX complexes exhibit chemical interactions with RNA,
DHFR mRNA obtained from in vitro transcription was incubated with various concentrations of
the RuLX complexes. An electrophoretic mobility shift assay was used to visualize the chemical
interactions resultant from the incubations. Our results suggest that RuL1 has the least interaction
with RNA; RuL2 appears to have a more pronounced interaction, while RuL3 shows the most
robust interaction with RNA. RuL2 and Rul3 incubated RNA showed a dose-dependent slowing
in migration due to RNA-RuLX interactions (Figure 21).
In the first gel image, the difference in migration appears to be minute and the RNA
bands migrated in smear patterns and with varying band density, both of which could be
indicative of RNA degradation (Figure 19).
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Figure 20: Agarose (1.0%) gel electrophoresis of RuL1, RuL2, & RuL3 treated, newly
transcribed RNA (3 µg) using increasing concentrations of each drug: 5, 50, 250, 500 µM.
RNA was incubated with RuLX complexes for 1.5 hours. Gel was run at 100V for 1 hour.
For the next set of experiments, a new transcription of RNA was carried out and
incubated with the RuLX complexes for half the duration (1.5 hours) in hopes of alleviating
degradation effects. The incubation mixture was run on an agarose gel at the same voltage and
time as the previous experiments (Figure 20). These results show that while the RNA bands ran
with constant density, the smearing persisted. This smearing is likely an artifact of the phenolchloroform purification process where some of the RNA may have underwent phenol
contamination and as a result, degraded (Figure. 20). Nonetheless, the migratory pattern persisted
where RuL2 and RuL3 show the most promising interactions with RNA (Figure 20). Moreover,
for better resolution, the experiment was repeated using higher percentage agarose (1.3%) and
using the revised RNA and RuLX complex incubation time of 1.5 hours. The gel was also run
for a longer time (4.5 hours) and at a lower voltage to ensure that heat generated from the
electrophoresis apparatus did not impair any RuLX-RNA interactions (Figure 21). The resultant
gel showed a step-wise slowing in migration from 50-200 µM concentrations of RuL2 and RuL3.
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RuL1 did not show a slowing in migration of RNA even at this higher resolution (Figure 21).
From the evidence garnered, it is likely that RuL2 and RuL3 are the only complexes possessing
strong enough chemical interactions with RNA to survive agarose electrophoresis. It is possible
that RuL2 and RuL3 form covalent adducts with the mRNA; however mass spectrometry studies
are needed to confirm this hypothesis.
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Figure 21: Agarose (1.3%) gel electrophoresis of RuL1, RuL2, & RuL3 treated RNA (2 µg)
using increasing concentrations of each drug: 5, 50, 250, 500 µM. RNA was incubated with
RuLX complexes for 1.5 hours. Gel was run at 50V for 4.5 hours.
RuL2- and RuL3-dependent slowing of RNA migration in agarose gel electrophoresis
may be due to their distinct chemical structure as compared to RuL1. RuL2 and RuL3 both
contain an ether moiety that bridges the NAMI-A-like and the ferrocene-like elements of their
structures, while RuL1 possesses an amine group in that location (Figure 8). This could yield
unique possibilities of reactivity for the RuL2 and RuL3 complexes that may not be available for
the RuL1 complex. Anti-cancer compounds like Bisulfan are DNA alkylators containing the
ether moieties that cause intrastrand cross-links between guanine bases in DNA double-helix
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strands, directly attacking DNA46. RuL2 and RuL3’s superior interaction with RNA compared to
RuL1 could be due to similar alkylating mechanisms with RNA.
Furthermore, RuL2 contains an imidazole moiety that has been shown to favor reactivity
with nucleic acids. The imidazole ring has been shown to be extremely reactive with biological
molecules, in the reactivity it possesses especially as an integral component of the amino acid
histidine, and its biological reactions. Moreover, imidazole’s antiproliferative and antimetastatic
contributions are evident in the success of NAMI-A as a candidate drug.
However, the nature of the RNA-RuLX interactions remains unclear. It is possible that
the interactions are covalent due to the stability of RuLX-RNA interactions under the pressure of
agarose gel electrophoresis. However more rigorous methods of study are needed to provide
evidence for this. Particularly, inductively coupled plasma mass spectrometry and matrixassisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry experiments
can shed great insight into these interactions. Using the aforementioned studies, NAMI-A was
found to form adducts with RNA at comparable frequencies to which it forms adducts with
DNA47. Moreover, MALDI-TOF studies also showed that when interacting with nucleic acids,
NAMI-A bound to oligonucleotides with strong coordination with either a single ruthenium atom
or a ruthenium atom linked to an imidazole ring47. It could be possible that the NAMI-A-like
portion of the RuLX complex coordinates with RNA using similar mechanisms. Mass
spectrometry studies can reveal more about the nature of these interactions than gel
electrophoresis.

3.4. Survey of RuLX inhibition of RNA directed in vitro translation
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Figure 22: A survey of RuLX translation inhibition. Normalized rate of reaction of in vitro
translation product using A) RuL1-treated RNA B) RuL2-treated RNA C) RuL3-treated RNA
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To explore the inhibitory effects of the RuLX compounds during in vitro translation, a
series of translation reactions were prepared using DFHR mRNA incubated with varying
concentrations of RuLX complexes. Thereafter, their translation products were examined using a
DHFR activity assay. The results of these studies suggest that there is a dose-dependent
inhibition of translation for all three complexes (Figure 22).
RuL1-treated RNA shows a significant reduction in DHFR activity at a concentration of
250 µM and onwards, with a reduction of over half the activity when compared to translation
using untreated RNA (Figure. 22). It also shows a counter-intuitive spike at concentrations of 5
µM and 500 µM RuL1 (Figure 22A). It seems as though there is more activity from DHFR
resultant from RNA treated with 5 µM RuL1 than untreated RNA (Figure. 22A). This is likely a
result of an experimental error; the experiment should be repeated multiple times to remedy this.
Similarly, it seems as though there is slightly more enzyme activity of DHFR translated from
RNA treated with 500 µM RuL2 than with RNA treated with 250 µM RuL2 (Figure 22B). This
is likely an artifact to the natural variability of the translation machinery. Although incubated
with the same components, in each new translation event, the translation machinery produces
varying amounts of DHFR RNA. This was demonstrated in that different translation events with
untreated RNA set up on the same day resulted in varied enzyme activity profiles. Moreover, it
could be that at 250 µM, all the possible sites of interaction on the DHFR mRNA are occupied;
this could be the concentration at which the DHFR mRNA is saturated with RuLX complexes.
Nevertheless, a more statistically robust exploration of the enzyme activity yielded from the
translation of RuL2-treated RNA is needed to account for variability of the translation output and
assign statistical significance to the trend.
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RuL2-treated RNA shows a plunge in DHFR activity at concentrations as low as 50 µM,
where there is less than half of the activity compared to untreated RNA (Figure 22B). The
reduction in activity appears to be dose-dependent, with the 250 µM having only a 1/5th of the
activity that DHFR produced from untreated RNA has (Figure 22B). Likewise, RuL3 shows a
significant reduction in DHFR activity by 50 µM, where there is a 40% reduction in DHFR
activity (Figure 22C). Dose-dependency is evident because enzyme activity decreases as the
concentration of RuLX complexes increases (Figure 22C). However, more statistically robust
explorations of these interactions are needed to assign statistical significance to the inhibition
and to establish the concentration at which there is a significant reduction in activity for each
complex. This would provide insight as to which complex is more effective at inhibiting RNA
driven in vitro translation.

3.5. Important controls to investigate nature of the translation inhibition
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Figure 23: Important controls to investigate the nature of inhibition A) Enzyme activity of
ribosomal proteins with 80 µM of RuLX complexes and supplied with DHFR mRNA for
translation B) Activity of DHFR enzyme incubated with 80 µM of RuLX complexes.
To ensure that the inhibition measured by the depletion of NADPH is due to the
impairment of translation by RNA-RuLX interactions, two controls were designed to tackle
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potentially confounding interactions between the RuLX complexes and proteins. Due to the fact
that previous work has shown that the RuLX complexes can chemically interact with both DNA
and proteins, it is important to establish a control to ensure that the reduction of enzyme activity
is not due to RuLX interactions with the ribosomal proteins or RuLX-induced impairment of
successfully translated, active, full-length DHFR.
To investigate whether the RuLX complexes inhibit efficient translation by impairing the
ribosomal proteins, ribosomal proteins were incubated with the highest exposure of RuLX
complexes for 3 hours and used in translation reactions that utilized clean DHFR mRNA as their
input. The highest exposure of RuLX to the ribosomal proteins was calculated to be 80 µM,
which corresponds to 500 µM RuLX-treated RNA. This is because when the RuLX-treated
RNA is entered into the translation reaction assembly, the overall concentration of RuLX
complexes exposed to the ribosomal proteins is diluted. The results of this survey suggest that
the complexes do interact with the translation machinery inhibiting efficient translation in an
unidentified fashion (Figure 23A). After incubation with all three complexes, RuL1 and RuL2
exhibit half the rate of NADPH consumption of the DHFR obtained un-incubated translational
machinery. RuL3 shows the most significant reduction of DHFR activity and thus, it is likely
that it is the mechanism that contributes the bulk of the inhibitory effects of the complex (Figure
23A). However, due to minimal materials and lack of time only an exploratory investigation of
these effects was conducted; a more robust investigation of the complexes is needed to delineate
not only whether the contribution of RuLX interactions with the ribosomal proteins is
statistically significant, but also whether it is responsible for the bulk of observed translation
inhibition.
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To investigate whether the RuLX complexes inhibit efficient translation by binding to
available, full-length DHFR, DHFR enzyme purchased form Sigma- Aldrich was treated with
RuLX complexes at the highest exposure (80 µM) and its activity was measured using a DHFR
assay (Figure 23B). The resultant data follows that RuL1-treated DHFR has similar activity to
untreated DHFR. RuL2 and RuL3 appear to reduce the activity of DHFR due to their interactions
with the enzyme. RuL2-treated DHFR has 20% less activity; it is possible that this small
reduction activity may be insignificant when compared to untreated DHFR. More statistically
robust experiments are needed to ensure this. Moreover, RuL3-treated DHFR consumes NADPH
at half the rates that untreated DHFR does (Figure 23B). Such a significant reduction in activity
could be indicative of such a vigorous interaction with the RuL3 complex that it degrades the
DHFR enzyme. However, due to minimal materials and lack of time, only an exploratory
investigation of these effects was conducted. A more robust investigation of the complexes is
needed to delineate whether the contribution of RuLX interactions with active DHFR is
statistically significant and whether it is responsible for the bulk of the inhibition of translation.

3.6. Follow-up studies investigating the impact and mechanism of RNA-RuL2
interactions in in vitro translation
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Figure 24: RuL2 dependent translation inhibition. A) Rate of consumption NADPH of DHFR
compared to DHFR incubated with 80 µM RuL2. t-test p>0.05 B) Normalized reaction rates
(to those of 0 µM incubation) of in vitro translation product obtained with RuL2-treated RNA.
ANOVA p>0.05
Due to the lack of significant agarose gel mobility changes in RuL1-treated RNA and the
significant reduction of activity when the RuL3-treated DHFR enzyme, RuL1 and RuL3
complexes were not investigated for further triplicate studies. RuL2, due to its prevalent mobility
shift in EMSA and seemingly minimal interaction with free DHFR enzyme, was selected for
further analysis.
To follow-up on RuL2’s ability to inhibit translation, triplicate translation events with
RuL2-incubated RNA were carried out and their translation product measured for DHFR
activity. While a dose-dependent trend is observed with regards to the reduction in DHFR
activity, statistical analysis does not find them to be different from the activity of DHFR
produced from untreated RNA or from each other [ANOVA p=0.321] (Figure 24B). Moreover, a
control to rule out interactions between RuL2 and full-length DHFR as the source for the bulk of
the inhibition was also conducted. Its results show that although there is a reduction in activity
due to RuL2 interactions with the enzyme, the reduction appears statistically insignificant [t-test
p= 0.287] (Figure 24B). In other words, the activity of untreated DHFR is essentially the same as
the activity of RuL2-treated DHFR. Nevertheless, a more robust analysis of the inhibitory effects
is needed due to the variability of the translation environment. An increase in replicates, from 3
to >5, could give data that is more insightful under statistical analysis. Moreover, outliers can
more easily be singled out when a larger sample size is available. While RuL2 shows a dosedependent reduction in enzyme activity when incubated with its DHFR mRNA, it is unlikely due
to RuL2 impairing the activity of fully translated DHFR. However, it could be due to RuL2
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impairment of the ribosomal proteins. This may account for some of the reduction in DHFR
activity. However, due to minimal materials and lack of time, only an exploratory investigation
of these effects was conducted. The data gathered so far, suggest that RuL2-dependet translation
inhibition may be due to its interaction with the mRNA.
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4. DISCUSSION
The explorative results obtained suggest that the RuLX complexes interact with both
nucleic acids and proteins. They also show that treating RNA with the RuLX can inhibit mRNA
directed in vitro translation. The data also suggest that the manner by which translation is
inhibited, is different for each RuLX compound. Although the mechanism responsible for the
bulk of the inhibition for each compounds is still unclear, more robust and specific experiments
can be conducted in the future to reveal this relationship.
These in vitro studies show promising results where these complexes show chemical
interactions with RNA and proteins. This allows for multiple avenues for inducing apoptosis
when entered into cells. Moreover, the unique reactivity of the ruthenium and iron metal centers
provides all three complexes with the potential to be selective against cancerous cells.
Ruthenium (III) requires activation by reduction that is more likely in the acidic
microenvironment of the tumor cells. Likewise, the ferroccene moiety can interconvert between
its inert state and its active ferrocenium form depending on the redox potential of the tumor
microenvironment. To support these findings, in vivo analyses of these complexes should be
carried out in human cancerous cultures or tractable cancer model systems like Saccharomyces
cerevisiae. An investigation of their antiproliferative properties as well as an analysis on their
accumulation within the cell is needed.

4.1 Study design limitations
It is important to note the limitations of the current study design, which uses the reduction
of enzyme activity as a measure of translation inhibition. This design does not reveal what aspect
of translation is affected or impaired by the RuLX complexes. Whether incubation with RuLX
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complexes inhibits translation initiation, which would result in no protein production, or cause
early termination of translation, which would give truncated, inactive DHFR enzyme, cannot be
determined using the current study design. Either of the aforementioned translation inhibition
events would result in identical reduction of enzyme activity.
To remedy this, experiments investigating the inhibition of peptide synthesis using either
35

S labeled methionine or fluorescently labeled lysine should be conducted. Both labels are easily

visualized using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The
canonical sequence of DHFR possesses seven methionine residues and nineteen lysine residues
suggesting that both labeling techniques would yield observable amplification of signal49.
Moreover, the labeling can held delineate what aspect of translation is inhibited. If the RuLX
complexes interfere with translation initiation, then there would be no successful peptide
synthesis and thus no detection of peptides when examined using SDS-PAGE. On the other
hand, if the interactions between the RuLX complexes and RNA cause a termination of
translation, peptide chains smaller than 21 kDa (the molecular weight of the DHFR enzyme)
would be observed using SDS-PAGE analysis. In the event that any of the RuLX complexes
cause termination, peptide-sequencing studies should be carried out uncover the amino acid
residues where termination frequently occurs. This could reveal more details of the downstream
consequences of RNA and RuLX interactions.

4.2. RuL1
RuL1 possessed little to no interaction with RNA when examined by agarose gel
electrophoresis. It is likely that the interaction between RuL1 and RNA, if any, is non-covalent.
It would then be unlikely for this complex to inhibit translation by forming chemical interactions
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with the RNA. It is important to note though, that the complex displayed translation inhibition in
concentrations greater than 250 µM. The mechanism of this inhibition is unlikely to be through
RNA-RuL1 interactions. However, it may be due to the complex’s protein-RuL1 interactions.
When investigated with DHFR enzyme and the translation machinery, RuL1 could impair the
activity of both enzymes suggesting that its molecular target may be proteins rather than nucleic
acids. In vivo studies investigating the binding affinity RuL1 to protein complexes are needed to
ascertain the aforementioned hypothesis.

4.3. RuL2
RuL2 seems to be the most promising of the complexes as it not only possesses an
interaction with RNA visible through an agarose EMSA, but also because it inhibits translation
at a lower concentration than its counterpart RuL1. RuL2 inhibits translation at similar
concentrations to RuL3. ICP-MS or MALDI-TOF analysis on the nature of the RNA-RuL2
interactions is needed to determine whether they are covalent. Also, such studies may provide
evidence as to whether its imidazole moiety contributes to its reactivity with RNA, as NAMI-A’s
imidazole moiety does. Nevertheless, the strength RNA-RuL2 interactions may cause
cytotoxicity in an in vivo model. Moreover, RuL2 appears to be able to weaken both DHFR and
ribosomal protein activity, thus providing more evidence that RuL2 is capable of binding
proteins. It could be the synergistic effects of both bonding to RNA and to proteins that allow
this complex to inhibit translation at a concentration of 50µM.

4.4. RuL3
RuL3 appears to be the most potent of the three complexes. Not only does it have a more
pronounced mobility shift when investigating its interactions with RNA, but it also shows a
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considerable ability to hinder both DHFR activity and efficient translation by the ribosomal
proteins when in incubated with them. Its interaction with RNA may allow for increased
cytotoxicity (compared to RuL1 and RuL2) in an in vivo model. Moreover, its ability to
significantly handicap protein activity is congruent with the EMSA evidence that suggested that
RuL2 might be able to degrade proteins (Figure.8). In vivo analyses could further elaborate on
RuL3’s antiproliferative potential.

4.5. Future Experiments
Inductively

coupled

plasma

mass

spectrometry

and

matrix-assisted

laser

desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry experiments should be
conducted to reveal the nature of the RNA-RuLX interactions. Moreover, studies investigating
the RuLX complexes binding affinity to DNA and RNA in the presence and absence of the
reductant ascorbate should be carried out to investigate the activation by reduction hypothesis.
These interactions should be characterized by both gel analysis and MALDI-TOF experiments.
Hostetter and colleagues found that Ru-nucleotide interactions, in the context of NAMI-A and
oligonucleotide biding, increase significantly in the presence of ascorbate. Furthermore, studies
to determine whether ascorbate discourages the interconversion between ferroccene and
ferrocenium salts of the RuLX complexes should also be conducted47. This is because, while
ruthenium (II) is reduced to its active form ruthenium (II), ferroccene, wielding Fe (II), needs to
be oxidized to its ferrocenium salt derivative, Fe (III), to possess antineoplastic and anti
proliferative properties27, 47.
To determine whether the inhibitory effects of RuLX are broad-range or specific to the
DHFR mRNA, equivalent translation inhibition studies using β-galactosidase, luciferase or green
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fluorescent protein mRNA as a new model should be conducted. All three aforementioned
enzymes have established activities that are easily detected by their respective enzyme activity
assays.

4.6. Concluding Remarks
It is evident from our studies that all three complexes possess the potential to inhibit
translation. However, due to the differing strength of interactions with RNA, it is likely that these
complexes inhibit translation through different mechanisms. More statistically robust studies
could reveal whether these complexes inhibit translation primarily by binding to RNA or by
denaturing proteins. An investigation on the antiproliferative and antineoplastic potential of the
RuLX complexes should be conducted in tractable cancer model systems like Saccharomyces
cerevisiae. Nevertheless, these complexes possess great potential to inhibit translation and
become a possible addition into the arsenal of metal-centered chemotherapeutic complexes.
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